Ask AI
ProCE Banner Series

Shifting Gears in Cardio–Renal–Metabolic Care: Harnessing Evidenced-Based Therapies to Optimize Patient Outcomes

Cardiology healthcare professionals (HCPs) are pivotal in ensuring timely initiation of evidence-based therapies for patients with cardio–renal–metabolic (CRM) diseases. However, clinical inertia continues to limit optimal care delivery. This program addresses hesitancy among HCPs and patients to initiate or continue guideline-directed medical therapy.

This event is not part of ACC.26 and is not sponsored or endorsed by the American College of Cardiology. This event does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Who Should Attend

This educational activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with HF and/or CKD (with or without diabetes).

All Events

Shifting Gears in Cardio–Renal–Metabolic Care: Harnessing Evidenced-Based Therapies to Optimize Patient Outcomes

Upcoming Events

March

29

2026

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton New Orleans Riverside, 2 Poydras Street, New Orleans, Louisiana 70130

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners who care for patients with HF and/or CKD (with or without diabetes).

Target Audience
This educational activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with HF and/or CKD (with or without diabetes).

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify persistent gaps in the care of patients with cardio-renal-metabolic disease and the clinical impact of delayed intervention

  • Evaluate emerging evidence on the broad benefits of SGLT2 inhibitors in CRM care to inform earlier initiation and sustained use in appropriate patients

  • Formulate strategies for effective patient counseling around integration of SGLT2 inhibitors into personalized care plans for patients with CRM conditions

Accreditation

This event does not qualify for continuing education (CME/CE) credit.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191